TgA86 mice overexpress mouse transmembrane TNF from a Δ1-12 mTNF-globin transgene. They develop with 100% incidence peripheral and axial joint pathology accompanied by new bone formation features, all characteristic of human SpA pathology. Read More

TgA86 mice overexpress mouse transmembrane TNF from a Δ1-12 mTNF-globin transgene. They develop with 100% incidence peripheral and axial joint pathology accompanied by new bone formation features, all characteristic of human SpA pathology. Read More
The TNFΔARE mouse model develops arthritis pathology together with Crohn’s like ileal inflammation with 100% penetrance. The co-occurence of two inflammatory pathologies provide a reliable in-vivo model for evaluating therapeutics targeting both pathologies. Read More
The Tg197 mouse model was successfully used in establishing the therapeutic efficacy of Remicade®, the first anti-TNF therapeutic to be successfully applied in the clinic, and is recommended by the FDA for screening potential anti-rheumatoid candidate drugs. Read More